GLAXOSMITHKLINE PLC Form 6-K July 12, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 12 July 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

	Details of PDMR/person closely associate Name	Ms E Walmsley		
b)	Position/status	Chief Executive Officer		
c) 2.	Initial notification/ amendment Details of the issuer, emission allowance	Initial notification market participant, auction		
a) b)	platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(c) has been conducted	(iii) each date; and (iv) each place		
a)	where transaction(s) has been conducted Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')		
b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan		
c)	Price(s) and volume(s)	Price(s)Volume(s)£16.04078 (partnership shares)£16.04078 (matching shares)		
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £16.0407		
e) f)	Date of the transaction Place of the transaction	2017-07-11 London Stock Exchange (XLON)		
	Details of PDMR/person closely associa Name Position/status	ted with them ('PCA') Mr R G Connor President, Global Manufacturing & Supply		
c)	Initial notification/	Initial notification		
2.	amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a) b)	Name LEI Details of the transaction (a): continue to h	GlaxoSmithKline plc 5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(s) has been conducted	n; (iii) each date; and (iv) each place		
a)	Description of the financial instrument			

b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan		
c)	Price(s) and volume(s)	Price(s)Volume(s)£16.04078 (partnership shares)£16.04078 (matching shares)		
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £16.0407		
e)	Date of the transaction	2017-07-11		
f)	Place of the transaction	London Stock Exchange (XLON)		
 a) b) c) 2. a) b) 	Details of PDMR/person closely associal Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(s) has been conducted	Mr S Dingemans Chief Financial Officer Initial notification e market participant, auction GlaxoSmithKline plc 5493000HZTVUYLO1D793 be repeated for (i) each type of ((iii) each date; and (iv) each place		
a)	Description of the financial instrument	('Ordinary Shares')		
b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan		
c)	Price(s) and volume(s)	Price(s)Volume(s)£16.04078 (partnership shares)£16.04078 (matching shares)		
d)	Aggregated information	16 Ordinary Shares		
	Aggregated volume Price	£16.0407		
e) f)	Date of the transaction Place of the transaction	2017-07-11 London Stock Exchange (XLON)		

1.	Details of PDMR/person closely associa	ted with them ('PCA')	
a)	Name	Mr N Hirons	
b)	Position/status	SVP, Global Ethics & Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
2)	Name	GlaxoSmithKline plc	
		5493000HZTVUYLO1D793	
0)			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
	where transaction(s) has been conducted	Ordinary shares of 25 pence each	
a)	Description of the financial instrument	('Ordinary Shares')	
		ISIN: GB0009252882	
		Acquisition of Ordinary Shares	
		under the Company's Share	
b)	Nature of the transaction	Reward Plan	
		Price(s) Volume(s)	
c)	Price(s) and volume(s)	£16.0407 8 (partnership shares)	
,		£16.0407 8 (matching shares)	
	A compacted information		
d)	Aggregated information	16 Ordinary Shares	
u)	A garageted volume Price	£16.0407	
	Aggregated volume Price		
e)	Date of the transaction	2017-07-11	
f)	Place of the transaction	London Stock Exchange (XLON)	
,			
1	Details of PDMR/person closely associa	ted with them ('DCA')	
	Name	Mr S A Hussain	
	Position/status	President, Global Pharmaceuticals	
0)	Initial notification/	Tresident, Olobar Tharmaceuticais	
c)	amendment	Initial notification	
	Details of the issuer, emission allowance	market participant auction	
2.	platform, auctioneer or auction monitor	market participant, auction	
a)	Name	GlaxoSmithKline plc	
	LEI	5493000HZTVUYLO1D793	
5)	Details of the transaction(s): section to b		
3.	instrument; (ii) each type of transaction;		
	where transaction(s) has been conducted		
		0 1 1 605 1	

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b)	Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)Volume(s)£16.04078 (partnership shares)£16.04078 (matching shares)	
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £16.0407	
e)	Date of the transaction	2017-07-11	
f)	Place of the transaction	London Stock Exchange (XLON)	
 a) b) c) 2. a) b) 3. a) 	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(s) has been conducted Description of the financial instrument	Mr D S Redfern Chief Strategy Officer Initial notification e market participant, auction GlaxoSmithKline plc 5493000HZTVUYLO1D793 e repeated for (i) each type of (iii) each date; and (iv) each place Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share	
,		Reward Plan Price(s) Volume(s) £16.0407 8 (partnership shares)	
c)	Price(s) and volume(s)	£16.0407 8 (matching shares)	
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £16.0407	
e)	Date of the transaction	2017-07-11	
f)	Place of the transaction	London Stock Exchange (XLON)	

	Details of PDMR/person closely associat			
	Name	Ms C Thomas		
b)	Position/status Initial notification/	SVP, Human Resources		
c)	amendment	Initial notification		
\mathbf{r}	Details of the issuer, emission allowance	market participant, auction		
2.	platform, auctioneer or auction monitor			
	Name	GlaxoSmithKline plc		
D)	LEI Details of the transaction(s): section to be	5493000HZTVUYLO1D793 e repeated for (i) each type of		
3.	instrument; (ii) each type of transaction;			
	where transaction(s) has been conducted			
		Ordinary shares of 25 pence each ('Ordinary Shares')		
a)				
		ISIN: GB0009252882		
		Acquisition of Ordinary Shares		
b)	Nature of the transaction	under the Company's Share		
,		Reward Plan		
		Price(s) Volume(s)		
c)	Price(s) and volume(s)	£16.0407 8 (partnership shares)		
		£16.0407 8 (matching shares)		
	Aggregated information	16 Ordinary Shares		
d)		£16.0407		
	rightender volume i nee			
e)	Date of the transaction	2017-07-11		
f)	Place of the transaction	London Stock Exchange (XLON)		
1)				
1.	Details of PDMR/person closely associat	ted with them ('PCA')		
	Name	Mr P C Thomson		
b)	Position/status	President, Global Affairs		
c)	Initial notification/ amendment	Initial notification		
-	Details of the issuer, emission allowance	market participant, auction		
2.	platform, auctioneer or auction monitor			
	Name	GlaxoSmithKline plc		
b)	LEI Details of the transaction(s): section to b	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place			
	where transaction(s) has been conducted			
		Ordinary shares of 25 pence each		
a)		('Ordinary Shares')		
		ISIN: GB0009252882		
b)	Nature of the transaction	Acquisition of Ordinary Shares		
		under the Company's Share		

Reward Plan

c)	Price(s) and volume(s)	Price(s)Volume(s)£16.04078 (partnership shares)£16.04078 (matching shares)	
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £16.0407	
e) f)	Date of the transaction Place of the transaction	2017-07-11 London Stock Exchange (XLON)	
a)	Details of PDMR/person closely associa Name Position/status Initial notification/	ted with them ('PCA') Dr P J T Vallance President, R&D Initial notification	
2. a)	amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI		
,	Details of the transaction(s): section to b instrument; (ii) each type of transaction; where transaction(s) has been conducted	e repeated for (i) each type of (iii) each date; and (iv) each place	
a)	Description of the financial instrument	('Ordinary Shares') ISIN: GB0009252882 Acquisition of Ordinary Shares	
b)	Nature of the transaction	under the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s)Volume(s)£16.04078 (partnership shares)£16.04078 (matching shares)	
d)	Aggregated information Aggregated volume Price	16 Ordinary Shares £16.0407	
e) f)	Date of the transaction Place of the transaction	2017-07-11 London Stock Exchange (XLON)	
a)	Details of PDMR/person closely associa Name	ted with them ('PCA') Mrs V A Whyte	

b) Position/status Company Secretary

c) 2.	Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor	Initial notification market participant, auction		
a)	Name	GlaxoSmithKline plc		
b)	LEI	5493000H	ZTVUYLO1D793	
	Details of the transaction(s): section to b			
3.	instrument; (ii) each type of transaction; where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')		
		ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan		
b)	Nature of the transaction			
c)	Price(s) and volume(s)		Volume(s) 8 (partnership shares) 8 (matching shares)	
d)	Aggregated information	16 Ordinary Shares £16.0407		
	Aggregated volume Price			
e)	Date of the transaction	2017-07-11		
f)	Place of the transaction	London Stock Exchange (XLON)		

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: July 12, 2017

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc